modelNimesulide
Extends from Pharmacolibrary.Drugs.ATC.M.M01AX17.
Information
| name: | Nimesulide | |
| ATC code: | M01AX17 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 0.19 | L |
| clearance: | 3.7 | L/h |
| other parameters in model implementation | ||
Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties, primarily used in the treatment of acute pain, symptomatic treatment of osteoarthritis, and primary dysmenorrhea. Due to potential hepatotoxicity, its use is restricted or banned in some countries and generally not approved in the US, but it remains approved in several European, Asian, and Latin American countries.
Pharmacokinetics
Healthy adult volunteers, oral administration; single dose PK.
References
Hanif, M, et al., & Khan, SM (2017). PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. Acta poloniae pharmaceutica 74(2) 489–495. PUBMED:https://pubmed.ncbi.nlm.nih.gov/29624254
Kim, MS, et al., & Kang, JS (2012). Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects. Journal of chromatographic science 50(5) 396–400. DOI:10.1093/chromsci/bms014 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22451531
Galligan, TH, et al., & Naidoo, V (2022). The non-steroidal anti-inflammatory drug nimesulide kills Gyps vultures at concentrations found in the muscle of treated cattle. The Science of the total environment 807(Pt 2) 150788–None. DOI:10.1016/j.scitotenv.2021.150788 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34619222
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)